Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes-Reference-Cited by-同舟云学术

Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

Published:2024-04-29 Issue:5 Volume:169 Page:
ISSN:0304-8608
Container-title:Archives of Virology
language:en
Short-container-title:Arch Virol

Author:

Das Soma^ORCID,Behera Padmanava,Shewale Dipeshwari J,Bodele Janhavi,Das Saumitra,Karande Anjali A

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00705-024-06024-4.pdf

Reference19 articles.

1. Guidelines on hepatitis B and C testing (2017) Geneva: World Health Organization; (http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981, accessed 17 July 2018).

2. Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053):946–952. https://doi.org/10.1038/nature04079

3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492. https://doi.org/10.1056/NEJM199811193392101

4. Christoph Sarrazin C, Hézode S, Zeuzem J-M, Pawlotsky (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 (Suppl 188–100. https://doi.org/10.1016/S0168-8278(12)60010-5

5. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl 1):i36–46. https://doi.org/10.1136/gutjnl-2012-302144